Adaptive Biotechnologies COO Julie Rubinstein sells $1m in stock
Adaptive Biotechnologies' COO Julie Rubinstein sold $1.01m in stock and exercised options for $432,706 in October 2026. ADPT stock is near its 52-week high at $29.84, up 106% year-over-year. Q2 results showed a wider-than-expected loss but revenue beat estimates. Analysts raised price targets, with BTIG and Goldman Sachs at $34 and $35 respectively, while Guggenheim set a $25 target.
How this was made
The 30-second read
Why it matters
The insider sale is a primary disclosure that may slightly weigh on the stock, but the broader earnings beat and analyst upgrades could offset the pressure.
Market read
Primary insider sale filing with modest size; limited immediate trading impact amid recent earnings beat.
Timing
post‑market today
Background
Adaptive Biotechnologies reported Q2 results earlier; the article focuses on the insider sale and mentions recent analyst upgrades.
Ticker impact
COO Julie Rubinstein sold $1.0M of ADPT shares via a Rule 10b5‑1 plan, a primary Form 4 filing.
likely modest pressure as market prices in the insider sell.
The filing is the first public disclosure of the sale; size is modest but signals insider cashing out.
Key entities
- executiveJulie Rubinstein
COO of Adaptive Biotechnologies, sold shares via 10b5‑1 plan.
- companyAdaptive Biotechnologies Corp
Biotech firm (NASDAQ:ADPT) reporting Q2 results and recent analyst activity.
